Online citations, reference lists, and bibliographies.

The Effect Of Hyperthermic Intraoperative Intraperitoneal Chemotherapy (HIPEC) As An Adjuvant In Patients With Resectable Pancreatic Cancer

Antonios-Apostolos K Tentes, Konstantinos M. Stamou, Nikolaos Pallas, Christina Karamveri, Dimitrios S. Kyziridis, Christos Hristakis
Published 2016 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract Background – aims: The long-term survival of pancreatic cancer is poor even after potentially curative resection. The incidence of local-regional failures is high. There is evidence that hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC) is effective in controlling the local-regional failures. The purpose of the study is to identify the effect of HIPEC after surgical removal of pancreatic carcinoma. Patients – Methods: Prospective study including 33 patients with resectable pancreatic carcinomas. All patients underwent surgical resection (R0) and ΗIPEC as an adjuvant. Morbidity and hospital mortality were recorded. The patients were followed-up for 5 years. Survival was calculated. Recurrences and the sites of failure were recorded. Results: The mean age of the patients was 67.8 ± 11.1 years (38–86). The hospital mortality was 6.1% (2 patients) and the morbidity 24.2% (8 patients). The overall 5-year survival was 24%. The mean and median survival was 33 and 13 months, respectively. The median follow-up time was 11 months. The recurrence rate was 60.6% (20 patients). Three patients were recorded with local-regional failures (9.1%) and the others with liver metastases. Conclusions: It appears that HIPEC as an adjuvant following potentially curative resection (R0) of pancreatic carcinoma may effectively control the local-regional disease. Prospective randomised studies are required.
This paper references
10.1097/01.sla.0000217673.04165.ea
One Thousand Consecutive Pancreaticoduodenectomies
John L. Cameron (2006)
10.1002/jso.10000
Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurence of peritoneal carcinomatosis.
Karsten Ridwelski (2002)
10.1056/NEJMoa032295
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
John P Neoptolemos (2004)
10.3322/canjclin.52.1.23
Cancer statistics, 2002.
Ahmedin Jemal (2002)
10.1080/02656736.2016.1190987
Cytoreductive surgery combined with hyperthermic intraperitoneal chemoperfusion for the treatment of gastric cancer: A single-centre retrospective study
Yinuo Tu (2016)
10.1002/bjs.1800820137
Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study.
Simon Roderick Bramhall (1995)
10.1056/NEJMoa1011923
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Thierry Conroy (2011)
10.3109/02656736.2015.1135485
Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?
Grace Hwei Ching Tan (2016)
10.3109/02656736.2016.1149233
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer
Karol Polom (2016)
10.1007/978-1-4613-1247-5_6
Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology.
Paul H Sugarbaker (1996)
10.1002/1096-9098(200005)74:1<36::AID-JSO9>3.0.CO;2-F
Prognostic factors after surgical resection for pancreatic carcinoma.
Paolo Magistrelli (2000)
Radical resection of pancreatic cancer.
Alexander Koliopanos (2008)
From the FROGHI (French Oncologic and Gynaecologic HIPEC Group)
N Bakrin (2013)
10.1002/(SICI)1096-9098(200004)73:4<212::AID-JSO5>3.0.CO;2-D
Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas.
Giacomo Benassai (2000)
Theoretical and experimental bases of intraperitoneal chemotherapy.
Robert L. Dedrick (1985)
10.1245/s10434-006-9182-x
A Systematic Review on the Efficacy of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei
Tristan D. Yan (2006)
10.1097/00000658-199912000-00006
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Jean H G Klinkenbijl (1999)
10.1002/cncr.20192
Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients.
Carlo Riccardo Rossi (2004)
10.1001/jama.297.3.267
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
Helmut Oettle (2007)
10.1245/s10434-009-0743-7
Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study
Charles C. Hsu (2009)
10.1097/00000658-199501000-00007
Long‐Term Survival After Resection for Ductal Adenocarcinoma of the Pancreas Is It Really Improving?
Samy S. Nitecki (1995)
10.1200/JCO.2004.10.012
Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.
Olivier Glehen (2004)
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma
TD Yan (2007)
10.1016/S0039-6060(99)70152-2
Relationship between hospital volume and late survival after pancreaticoduodenectomy.
John D. Birkmeyer (1999)
10.32388/22oioy
Pancreatic carcinoma.
Oluwole Gbolagunte Ajao (1980)
10.1177/000313481307900624
Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Sarcomatosis
Reese W Randle (2013)
Intraperitoneal gemcitabine chemotherapy as an adjuvant treatment for patients with resected pancreatic cancer: Phase II and pharmacologic studies
Paul H Sugarbaker (2012)
10.1097/SLA.0000000000001225
Is the Combination of Distal Pancreatectomy and Cytoreductive Surgery With HIPEC Reasonable?: Results of an International Multicenter Study
Lilian Schwarz (2016)
10.1097/01.SLA.0000041266.10047.38
Prognostic Factors Following Curative Resection for Pancreatic Adenocarcinoma: A Population-Based, Linked Database Analysis of 396 Patients
Jonathan E Lim (2003)
10.1001/archsurg.1985.01390320023003
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Martin H. Kalser (1985)
Pancreatic carcin
AL Warshaw (1992)
10.1016/j.ejso.2013.09.030
Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients.
Naoual Bakrin (2013)
10.1093/annonc/mdl428
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma
Tristan D. Yan (2007)
Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans.
James L. Speyer (1981)
10.1016/S0002-9610(05)80406-4
Prognostic indicators for survival after resection of pancreatic adenocarcinoma.
R J Geer (1993)
10.1200/JCO.2011.36.5742
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Daniel D. Von Hoff (2011)
10.1016/j.ijsu.2016.02.064
Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head is justified in elderly patients: A Retrospective Cohort Study.
Bernhard W. Renz (2016)
10.3748/wjg.v21.i11.3157
Update on the management of pancreatic cancer: surgery is not enough.
Daniel Ansari (2015)
10.1155/2012/506571
Preliminary Results of Hyperthermic Intraperitoneal Intraoperative Chemotherapy as an Adjuvant in Resectable Pancreatic Cancer
Antonios-Apostolos K Tentes (2012)
10.1186/s12957-015-0525-6
Retrospective analyses of trends in pancreatic surgery: indications, operative techniques, and postoperative outcome of 1,120 pancreatic resections
Uwe A Wittel (2015)
10.1177/030089169808400619
Pharmacokinetics of Intraperitoneal Gemcitabine in a Rat Model
Sophie R Pestieau (1998)
10.3238/arztebl.2008.0255
Pancreatic cancer--low survival rates.
Hans Günther Beger (2008)
10.1053/j.gastro.2005.04.001
Pancreatic cancer: basic and clinical aspects.
Günter Schneider (2005)
Theoretical and experimental bases of intraperitoneal chemotherapy.
Dedrick Rl (1985)
10.1016/S0090-3671(08)79093-1
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial
Timothy J. Eberlein (2008)



This paper is referenced by
10.1002/jso.24813
Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions—A systematic review
William F. Morano (2018)
Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer.
Antonios-Apostolos K Tentes (2018)
10.1007/978-981-10-7053-2_17
Clinical Trials in CRS and HIPEC: Ongoing Trials and Future Directives
William F. Morano (2018)
10.1007/978-3-319-58256-6_19
The Role for Palliative Surgical Interventions in Pancreatic Cancer
Alexandra G Lopez-Aguiar (2018)
10.18632/oncotarget.14745
Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: a systemic review and meta-analysis
Feng Cao (2017)
10.1080/02656736.2017.1302100
Hyperthermic chemotherapy intra-abdominal laparoscopic approach: development of a laparoscopic model using CO2 recirculation system and clinical translation in peritoneal carcinomatosis
Susana Sánchez-García (2017)
10.1186/s11658-019-0153-1
Concentration changes in gemcitabine and its metabolites after hyperthermia in pancreatic cancer cells assessed using RP-HPLC
Hb Jin (2019)
10.1080/02656736.2019.1710270
Locoregional peritoneal hyperthermia to enhance the effectiveness of chemotherapy in patients with peritoneal carcinomatosis: a simulation study comparing different locoregional heating systems.
H. Petra Kok (2020)
10.1080/02656736.2017.1306119
Ninety percent of the adverse outcomes occur in 10% of patients: can we identify the populations at high risk of developing peritoneal metastases after curative surgery for colorectal cancer?
Charles Honoré (2017)
10.1080/02656736.2017.1289565
Update on clinical trials in colorectal cancer peritoneal metastasis
Amandine Pinto (2017)
10.1016/j.suronc.2017.01.002
Strategies to improve local control of resected pancreas adenocarcinoma.
Paul H Sugarbaker (2017)
10.1016/j.hpb.2017.08.018
Tumor manipulation during pancreatic resection for pancreatic cancer induces dissemination of tumor cells into the peritoneal cavity: a systematic review.
M Willemijn Steen (2018)
Semantic Scholar Logo Some data provided by SemanticScholar